Wortmannin

For research use only. Not for use in humans.

目录号:S2758 别名: KY 12420

Wortmannin Chemical Structure

Molecular Weight(MW): 428.43

Wortmannin是一种首次命名的PI3K抑制剂,在无细胞试验中IC50为3 nM,对 PI3K 家族的选择性较低。Wortmannin 可抑制自噬体的形成,并有效抑制DNA-PK/ATM,在无细胞试验中IC50为16 nM和150 nM。Wortmannin 也能抑制 PLK1 的活性。

规格 价格 库存 购买数量  
10mM (1mL in DMSO) RMB 1441.24 现货
RMB 899.84 现货
RMB 1414.71 现货
RMB 2210.53 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的Wortmannin发表文献146篇:

产品安全说明书

PI3K抑制剂选择性比较

生物活性

产品描述 Wortmannin是一种首次命名的PI3K抑制剂,在无细胞试验中IC50为3 nM,对 PI3K 家族的选择性较低。Wortmannin 可抑制自噬体的形成,并有效抑制DNA-PK/ATM,在无细胞试验中IC50为16 nM和150 nM。Wortmannin 也能抑制 PLK1 的活性。
靶点
PI3K [3]
(Cell-free assay)
DNA-PK [12]
(Cell-free assay)
ATM [12]
(Cell-free assay)
MLCK [1]
(Cell-free assay)
3 nM 16 nM 150 nM 170 nM
体外研究

钙或肽底物不影响Wortmannin对MLCK的抑制,但高浓度的ATP会减弱此种抑制。Wortmannin直接与MLCK催化结构域相互作用,导致不可逆转的酶活性减弱。Wortmannin对cAMP依赖蛋白激酶,cGMP依赖的蛋白激酶,钙调蛋白依赖激酶II,和蛋白激酶C均无抑制作用。[1] Wortmannin抑制由fMLP诱导的PtdInsP3(磷脂酰肌醇3,4,5-三磷酸化)形成,IC 50为5 nM 。在人中性粒细胞中,Wortmannin剂量为100 nM时可发挥完全抑制作用,增加PtdInsP2水平,且对PtdInsP和 PtdIns没有影响;Wortmannin可动态调控F-actin水平对fMLP刺激的肌动蛋白聚合无影响。[2]在RBL-2H3细胞中,Wortmannin通过结合110-kDa蛋白,不可逆的抑制磷酸肌醇3激酶(PI3-kinase)活性(IC 50为3 nM)对,对Pi4-kinase没有影响。Wortmannin也抑制Fc epsilon RI介导的组胺分泌和白三烯释放,对酪氨酸激酶Lyn无影响。[3]在大鼠脂肪细胞中,剂量为0.1 μM的 Wortmannin可完全抑制胰岛素诱导的己糖吸收,二不影响异丙肾上腺素刺激的脂肪分解活性。[4] 在人脐静脉内皮细胞中,在IGF-1的存在下,Wortmannin抑制胰岛素诱导一氧化氮生产,IC50为500nM。[5]在中国仓鼠卵巢细胞中, Wortmannin以50 μM剂量可抑制DNA双链断裂(DSB)修复,但对DSB水平无影响或单链断裂(SSB)酶活无影响。Wortmannin可加强电离辐射(红外)诱导的细胞毒作用,但本身无毒性。[6] Wortmannin抑制水球样激酶(PLK 1)活性,IC 50为24nM,造成细胞G 2 / M阻滞。[7] 在人巨噬细胞中,Wortmannin增加 Toll样受体(TLR)介导的白细胞介素- 6的积累,EC 50 = 50 nM。在小鼠巨噬细胞中,Wortmannin显着增强TLR诱导一氧化氮合酶(iNOS)的表达和亚硝酸盐积累。Wortmannin激活核因子-κB和上调细胞因子mRNA量。[8] Wortmannin也抑制水球样激酶(PlK)1和PlK 3,在有丝分裂中发挥重要作用。Wortmannin治疗可能导致可减少由DNA损伤诱导的p53丝氨酸20位磷酸化。[9] 在SW 1990细胞中,Wortmannin可抑制透明质酸诱导Akt磷酸化和细胞运动/迁移。[10]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
A459 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXGyMlUh|ryP MWexMVQh\A>? MVfEUXNQ NFfRXGVmdmijbnPld{Bk\WyuIHfyc5d1cCCrbnjpZol1cW:wIITy[YF1dWWwdDD3bZRpKHSjbX;4bYZmdg>? MmrhNlU1QTB|OEO=
H1703 NX3iS|FqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mmj5Nk42KM7:TR?= NGe0[ZAyNTRiZB?= M2PCN2ROW09? MVflcohidmOnczDj[YxtKGe{b4f0bEBqdmirYnn0bY9vKHS{ZXH0cYVvfCC5aYToJJRidW:6aX\lci=> MXyyOVQ6ODN6Mx?=
HUVECs M2LhdGN6fG:2b4jpZ4l1gSCDc4PhfS=> M4HsfVExOCCwTR?= NHq4N2wzPCCq NV:xXGJu[XS2ZX71ZZRmeyC2aHWgZYJzd2ejdHn2[UBm\m[nY4TzJI9nKGOjbInjc5NqdiCxbjDWVmkucW6mdXPl[EBkgXSxdH;4bYNqfHl? NWHZS5hoOjV2NUCxPFY>
APRE-19 NWW4UY5ISXCxcITvd4l{KEG|c3H5 NWe3NZRMPSEQvF2= MnzJNlQhcA>? NGnCNmli[m:uaYPo[ZMhTkycLX3l[IlifGWmIIDyc{1{fXK4aY\hcE9idnSrLXHwc5B1d3OrczDhZ5Rqfmm2eR?= NYXoOVJROjV|Mkm2NVc>
MDA-MB-231 Mo\iRZBweHSxc3nzJGF{e2G7 NI[yWYwyyqEQvF5CpC=> NXfRdXN2PDhiaB?= NGjhSWVFVVOR NFL2XHNl\WO{ZXHz[ZMhfGinIHPlcIwhe3W{dnn2ZYwhfHKnYYTl[EB4cXSqIEK1JO69VSCxZjDGNUBweiCIMjFCpC=> MXSyOVMxODl|Mh?=
MCF7 NHXZUnFHfW6ldHnvckBCe3OjeR?= M4TWU|ExOCCwTR?= MmXZNlQhcA>? M4rseoVtcW2rbnH0[ZMhTTJvaX7keYNm\CCDUlWtUJVkKGGldHn2bZR6 MXqyOVE4OjV3Nx?=
HT-29  MoD3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWKxMlXDqML3TR?= M4TiVlk3KGh? NXjnN25w\GWlcnXhd4V{KGOnbHyg[5Jwf3SqIIfobYNpKGOjbjDi[UBqdmirYnn0[YQh[nliS2nORS=> MoLQNlUxOTJzMkO=
MO59K  NVXFRVg1S3m2b4TvfIlkcXS7IFHzd4F6 M2jYdlXDqM7:TR?= M3\yVFch\A>? NGDIWVFFVVOR NFTXTVVmdmijbnPld{B1cGViY4n0c5RwgGmlaYT5JI9nKGW2b4Dvd4ll\SCxcjDjbZNxdGG2aX6= NYrT[XV[OjR7NUO1OlE>
MO59J NH\FS4FEgXSxdH;4bYNqfHliQYPzZZk> MVe1xsDPxE1? M1O3Wlch\A>? MkLWSG1UVw>? MoPY[Y5p[W6lZYOgeIhmKGO7dH;0c5hq[2m2eTDv[kBmfG:yb4Pp[IUhd3JiY3nzdIxifGmw M4nvTVI1QTV|NU[x
MO59K  NILSOGFCeG:ydH;zbZMhSXO|YYm= NYD1foxvOTBizszN MofiNlQhcA>? MlewSG1UVw>? M13PTolv[3KnYYPld{B1cGViRGPCJIxmfmWuIHnu[JVk\WRiYomg[ZRweG:|aXTlJI9zKGOrc4DsZZRqdg>? NEn6c2MzPDl3M{W2NS=>
MO59J MXPBdI9xfG:|aYOgRZN{[Xl? MV[xNEDPxE1? NFrmWJgzPCCq MlvISG1UVw>? NY\yOlZPcW6lcnXhd4V{KHSqZTDEV2IhdGW4ZXygbY5lfWOnZDDifUBmfG:yb4Pp[IUhd3JiY3nzdIxifGmw NU\NdXVrOjR7NUO1OlE>
HepG2 NFzifYdHfW6ldHnvckBCe3OjeR?= NEDCb3AyODBibl2= Moe5NE42KGh? NYrPOWFPTE2VTx?= M{[1c4Jtd2OtczDNRU1qdmS3Y3XkJGFsfCCyaH;zdIhwenmuYYTpc44> MnX6NlQ5PjN|NUC=
A549  MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkPRN{DDvU4EoB?= MXuyJIg> MXrzeZBxemW|c3XzJJBmdWW2cnX4[YQucW6mdXPl[EBCc3RiYX7kJGdUUzQQsjDhZ5RqfmG2aX;uMEBUNXCqYYPlJIFzemW|dDygZ4VtdCCjcH;weI9{cXNiYX7kJINie3Cjc3WtN{Bi[3SrdnH0bY9v MkDjNlQ5PDd6NkO=
A549  MUnGeY5kfGmxbjDBd5NigQ>? MW[xNOKh|ryvwrC= MX[xOkBp MnPSSG1UVw>? NF7uUo9ud2S3bHH0[ZMhfGinIFnBWkBz\XCuaXPheIlwdiCjbnSgZ4F2e2W|IILleIVvfGmxbjDv[kBPWCCrbjD0bIUhdnWlbHX1d{4> NHTN[WwzPDhyMkGxNS=>
SK-N-LO NYHDd4w{TnWwY4Tpc44hSXO|YYm= NHvnW20yODBibl2= NX;LXo57OC53IHi= NX;rdXlZ\GWlcnXhd4V{KHSqZTDzeIlufWyjboSg[YZn\WO2czDv[kBud3KyaHnu[UBwdiCDa4SgdIhwe3Cqb4L5cIF1cW:w M3XCdVI1PjV2NkC2
HL-60 NIqyRVBHfW6ldHnvckBCe3OjeR?= M4nZdlAvOcLizszN MXm3NkBp NW\0OXpI[myxY3vzJIRie2G2aX7pZk1qdmS3Y3XkJINmdGxiZHnm[oVz\W62aXH0bY9v Mn7kNlQ3ODd{N{O=
HepG2  NVT2eINqTnWwY4Tpc44hSXO|YYm= MUmyNFAhdk1? NY\HNXk{OC53IHi= MkjYZZR1\W63YYTld{BHd3iRIIDoc5NxcG:{eXzheIlwdg>? NH\CXIYzPDV|NUG5Ni=>
H520 M{P5cmZ2dmO2aX;uJGF{e2G7 M1mzZVExyqEQvF2= MoPWNUBp NXXwSXQzTE2VTx?= MYrk[YNz\WG|ZYOgZ4VtdHWuYYKgdIhwe3Cqbz3BT3QheHKxdHXpckBt\X[nbIO= MUGyOFQ1Pzl|NR?=
H1975 M2Ht[GZ2dmO2aX;uJGF{e2G7 MnfsNVDDqM7:TR?= MmjZNUBp MX3EUXNQ MVnk[YNz\WG|ZYOgZ4VtdHWuYYKgdIhwe3Cqbz3BT3QheHKxdHXpckBt\X[nbIO= NEnoNnYzPDR2N{mzOS=>
MG-63 M2fXU2Fxd3C2b4Ppd{BCe3OjeR?= NILZcFAyOCEEtV2= MVuxNkBp M3S5SYVvcGGwY3XzJGRRNWmwZIXj[YQh[XCxcITvd4l{ NUG4W4pqOjR|NUizNFE>
5637 MV\BdI9xfG:|aYOgRZN{[Xl? NVH6OWp[OTEEoN88US=> MUe0NEBucW5? M4DITpJmfmW{c3XzJJAzOVeDRkGg[ZhxemW|c3nvckwhS0SNIHX4dJJme3Orb36sJIFv\CClZXzsJIlvcGmkaYTpc44hcW6mdXPl[EBjgSCodXPvbYRidg>? M2HXeFI1OzN|OE[4
HEK-293 MoqxSpVv[3Srb36gRZN{[Xl? MXSxOVBvVQ>? MmXLNVYhcA>? M3TP[WROW09? NXjHR5Yy\GWlcnXhd4V{KEOUVDDhZ5Rqfmm2eR?= MlHBNlQ{OjR|Nk[=
SW480  MVTGeY5kfGmxbjDBd5NigQ>? NVi1Wo5POTVybl2= M37nVVIxKGh? M2SxXmROW09? M{\jfJJm\HWlZYOgZ4VtdHWuYYKgZYNkfW23bHH0bY9vKG:oIN8yMYNifGWwaX6= NYT2e49DOjR|MkSzOlY>
HepG2 NVW4Tm5HTnWwY4Tpc44hSXO|YYm= NF32cIUyODBibl2= Mn\PNlQhcA>? Ml3pZZR1\W63YYTld{B1cGViY3;sc45q\XNib3[geIhmKHS3bX;yJINmdGy|IIfpeIghfXC{ZXf1cIF1cW:wIH;mJGFsfDF? NHPQfFkzPDJ7N{WxNC=>
HCT 116  NFP3WGNHfW6ldHnvckBCe3OjeR?= NG\FfpgyODBibl2= NYrScVMyOjRiaB?= NEfSfIdifHSnboXheIV{KHSqZTDjc4xwdmmnczDv[kB1cGVidIXtc5Ih[2WubIOge4l1cCC3cILl[5Vt[XSrb36gc4YhSWu2MR?= MWCyOFI6PzVzMB?=
BEL/FU MWDGeY5kfGmxbjDBd5NigQ>? NEXvUFEyKG2P M1vqVlI1KGh? NFTC[3pl\WO{ZXHz[ZMheHKxdHXpckBt\X[nbIOgc4YhfGinIGDJN2swSWu2IIDheIh4[Xl? M3;JeVI1OjN{MEm5
Huh7  MlrrSpVv[3Srb36gRZN{[Xl? NV3hUFV[O8LizszN MkPQNUBp MYny[YR2[2W|IITo[UB3cXK3czDlcpRzgSCrboTvJJRp\SClZXzsdy=> M{DrZ|I1OTh2MUm2
A-375 Ml64RZBweHSxc3nzJGF{e2G7 MUm0M|gh|ryP M4DONlI1KGh? M3vGTYVvcGGwY3XzJHRTSUmOLXnu[JVk\WRiYYDvdJRwe2m|wrC= Mmn1NlQyOTNzN{O=
A-375-TS  MmTqRZBweHSxc3nzJGF{e2G7 MoTXOE85KM7:TR?= NUi1N5RLOjRiaB?= MoL1[Y5p[W6lZYOgWHJCUUxvaX7keYNm\CCjcH;weI9{cXQEoB?= Mn\mNlQyOTNzN{O=
Mel-HO NV[xTVZKSXCxcITvd4l{KEG|c3H5 M17OdlQwQCEQvF2= NWm4ZmpyOjRiaB?= M4LCbYVvcGGwY3XzJHRTSUmOLXnu[JVk\WRiYYDvdJRwe2m|wrC= NVjmTZc{OjRzMUOxO|M>
Mel-HO-TS NXH4cHNTSXCxcITvd4l{KEG|c3H5 MnLHOE85KM7:TR?= NEnFfWkzPCCq NIn5bm1mdmijbnPld{BVWkGLTD3pcoR2[2WmIHHwc5B1d3Orc9Mg MYKyOFEyOzF5Mx?=
MeWo NX;xTI9ISXCxcITvd4l{KEG|c3H5 MnHJOE85KM7:TR?= MmK3NlQhcA>? Ml;N[Y5p[W6lZYOgWHJCUUxvaX7keYNm\CCjcH;weI9{cXQEoB?= NVzO[GxyOjRzMUOxO|M>
Mel-2a NIDGVo9CeG:ydH;zbZMhSXO|YYm= NH\4c3U1NzhizszN Mn3nNlQhcA>? NX\L[YpC\W6qYX7j[ZMhXFKDSVytbY5lfWOnZDDhdI9xfG:|aYRCpC=> MWiyOFEyOzF5Mx?=
MDA-MB-231 NVm2NWk3TnWwY4Tpc44hSXO|YYm= Mnj1NQKBmzRyMDDuUS=> NXT0XGloPCCq M3my[pN2eHC{ZYPz[ZMhSWu2IIDoc5NxcG:{eXzheIlwdiCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NFXubHIzOjlyNkK1PS=>
MDA-MB-231 NFfSUGZHfW6ldHnvckBCe3OjeR?= MonZOFAxKG6P MlfMOEBp MmH3[IVkemWjc3XzJG1OWC17IHHu[EBKVC16IIDyc5RmcW5iaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MWGyNlkxPjJ3OR?=
Jurkat MlHJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlzvNE4zPS1zLkK1JO69VQ>? M{XXdlI1NzR6IHi= Mn3xSG1UVw>? Mk\wbY5pcWKrdIOgZ4VtdCCycn;sbYZmemG2aX;uJIlvKGKxdHigeIlu\S1iYX7kJIRwe2VvIHTldIVv\GWwdDDtZY5v\XJ? NFPOZosyQTd3N{G4OS=>
Namalwa MoX2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGe1OocxNjJ3LUGuNlUh|ryP MlTWNlQwPDhiaB?= M4nNTGROW09? MnnhbY5pcWKrdIOgZ4VtdCCycn;sbYZmemG2aX;uJIlvKGKxdHigeIlu\S1iYX7kJIRwe2VvIHTldIVv\GWwdDDtZY5v\XJ? NGTZZ|cyQTd3N{G4OS=>
Jurkat NVrvPIdFSXCxcITvd4l{KEG|c3H5 NUfD[G53OC5{NT2xMlI2KM7:TR?= MUKyOE81QCCq NWWxRYQxTE2VTx?= NXTNcmE4cW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBjd3SqIITpcYUuKGGwZDDkc5NmNSCmZYDlcoRmdnRibXHucoVz NGnOdmwyQTd3N{G4OS=>
Namalwa M1;GbmFxd3C2b4Ppd{BCe3OjeR?= MV:wMlI2NTFwMkWg{txO M4f0fVI1NzR6IHi= NHrXZnVFVVOR MUTpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHLveIghfGmvZT2gZY5lKGSxc3WtJIRmeGWwZHXueEBu[W6wZYK= NI\ObnYyQTd3N{G4OS=>
K562 NUKxO|lDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmrjNlQhcA>? M{\QPGlEPTB;MkZCtVAvOTRibl2= Mo\BNVk3PjJ|NkG=
SW1990 MXrGeY5kfGmxbjDBd5NigQ>? MnG3NE4xOS1zIN88US=> M{fmPFEhcA>? NH36d3JqdmirYnn0d{BJSS2rbnT1Z4VlKEGtdDDwbI9{eGixconsZZRqd25? MnfUNVk1PjlyMkC=
RT112  MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1HVOFExyqEQvF2= MkLENlQhcA>? NVq4fpRwTE2VTx?= NV3OO2U2\GWlcnXhd4V{KHSqZTDwdo9xd3K2aX;uJI9nKEd{L12gZ4VtdHN? NIDiSY4yQDd6N{izNi=>
MHG-U1 NYHYVmRsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHfFOlIyOMLizszN MV2yOEBp Ml[xSG1UVw>? NEe0W4Nl\WO{ZXHz[ZMhfGinIIDyc5BwenSrb36gc4YhTzJxTTDj[Yxtew>? NVjPb3FsOTh5OEe4N|I>
SMMC-7721 NFO4SJJCeG:ydH;zbZMhSXO|YYm= NHTTepAzODEEoH7N NWXFVo9vOjRiaB?= MkPHbY5kemWjc3XzJGNJYC2rbnT1Z4VlKGGyb4D0c5Nqew>? MYmxO|U2PzF7MR?=
SMMC-7721 NVLkO|JwTnWwY4Tpc44hSXO|YYm= NUTzSHNWOjBywrDuUS=> NUHnSHZmOjRiaB?= MkTaeZAuemWpdXzheIV{KM7{MTy0S3QyKGW6cILld5Nqd25? NHXSb|QyPzV3N{G5NS=>
HeLa NWrIT3oxTnWwY4Tpc44hSXO|YYm= MUGxNFDDqG6PwrC= MoDnNUBp M1\Qc4FtfGW{czD0bIUhdW:{cHjvcI9ogSCxZjD0bIUhfHKjboPm[ZJzcW5icnXjfYNtcW6pIHPvcZBienSvZX70 Mne5NVY5QTB7MUW=
MRC5VI NXfRN5lyTnWwY4Tpc44hSXO|YYm= MlfaNVIvPSCvTR?= MlflNE42KGh? M{O2TmROW09? M2O4OYFjd2yrc3jld{B1cGViU3XyOFc{N1SqckOwPOKheGixc4Doc5J6dGG2aX;uJI9nKEGtdGDLRuKh NFj1b2kyPjJ{N{O5OC=>
AT5BIVA NVLZUpFJTnWwY4Tpc44hSXO|YYm= M1TU[FEzNjVibV2= M{PhSlAvPSCq Mmm4SG1UVw>? M1vRXYFjd2yrc3jld{B1cGViU3XyOFc{N1SqckOwPOKheGixc4Doc5J6dGG2aX;uJI9nKEGtdGDLRuKh MoLVNVYzOjd|OUS=
M059J NXu3cpNiTnWwY4Tpc44hSXO|YYm= NXLz[HFoOTJwNTDtUS=> NVfOfpZtOC53IHi= NFflUHBFVVOR M4Dlc4Fjd2yrc3jld{B1cGViU3XyOFc{N1SqckOwPOKheGixc4Doc5J6dGG2aX;uJI9nKEGtdGDLRuKh NXvGO5F5OTZ{MkezPVQ>
HeLa NWDpT4xYTnWwY4Tpc44hSXO|YYm= M3rDeFEzNjVibV2= MnrMNE42KGh? M1jJTWROW09? NFXmOmti[m:uaYPo[ZMhfGinIGPldlQ4Oy:WaIKzNFjDqHCqb4PwbI9zgWyjdHnvckBw\iCDa4TQT2LDqA>? MVixOlIzPzN7NB?=
N2a MVfBdI9xfG:|aYOgRZN{[Xl? NXPFZYJbOC5zLUGwJO69VQ>? NFX0WogzKGh? NVXkOoE{cW6mdXPld{Bl\WO{ZXHz[YQh[2WubDD2bYFjcWyrdImgbY4h[SClb37j[Y51emG2aX;uMYRmeGWwZHXueEBu[W6wZYK= MUGxOVg1Ojd4Nx?=
Jurkat  M123[WtqdmG|ZTDBd5NigQ>? NHjmOYlKSzVyIH;mJFI1KG6P MkC0NVU3PjR3MUm=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p-AKT / AKT / p-GSK3β / GSK3β / Bcl-xl / Bax / Caspase-3 / Cleaved caspase-3; 

PubMed: 25344912     


Four esophageal cancer cell lines were treated with different concentrations of wortmannin for 48 h, and cell lysates were collected for Western blot analysis of p-AKT, AKT, p-GSK3β, GSK3β, Bcl-xL, Bax, caspase-3, and cleaved caspase-3.

25344912
Immunofluorescence
DNMT1; 

PubMed: 24001151     


PC3 cells were treated with DMSO or wortmannin (1 μM) for 24 hours. DNMT1 and DNMT3B cellular localization was visualized by immunofluorescent staining. After 24h of treatment, cells were fixed in methanol, incubated with the indicated antibodies, stained with Alexa Fluor 594-tagged secondary antibodies and counterstained with DAPI. Slides were then mounted and examined under a fluorescence microscope. The bright field images of PC3 cells treated with DMSO or wortmannin (1 μM) for 24 hours are shown (right panel).

24001151
Growth inhibition assay
Cell viability; 

PubMed: 25344912     


MTT assay was used to determine the effects of different concentrations of wortmannin on viability of esophageal cancer cells lines KYSE150, HKESC-1, KYSE270, and T.Tn. Bars, SD; * P < 0.05; **, P < 0.01; ***, P < 0.001 compared with DMSO-treated cells.

25344912
体内研究 Wortmannin剂量为1mg/kg可抑移植瘤小鼠中SW1990的腹膜转移,无重量损失。[10] Wortmannin抑制在小鼠正常组织(肺,心脏和脑组织匀浆)及肿瘤组织中的phosphatidylinositide 3- B激酶(PKB)/磷酸化Akt,在剂量为0.7 mg/kg时无死亡或急性毒性。与gemcitabine联合使用时,可大大增加细胞凋亡和抑制原位肿瘤生长,两种药物单独使用都无以上效果。[11]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

动物实验:[11]
- 合并
  • Animal Models: 人胰腺癌细胞 PK1s.c.和原位注入SCID免疫缺陷小鼠。
  • Dosages: 0.175, 0.35, 和0.7 mg/kg
  • Administration: 静脉注射
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 85 mg/mL (198.39 mM)
Water Insoluble
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
5% DMSO+40% PEG 300+5% Tween 80+ddH2O
5mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 428.43
化学式

C23H24O8

CAS号 19545-26-7
储存条件 粉状
溶于溶剂
别名 KY 12420

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % ddH2O
计算重置

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

相关PI3K产品

Tags: 购买Wortmannin | Wortmannin供应商 | 采购Wortmannin | Wortmannin价格 | Wortmannin生产 | 订购Wortmannin | Wortmannin代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID